This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for June 4, 2024
by Zacks Equity Research
Companies In The Article Are:NVDA, MRK,MRNA, SPOT, SRCL and WM
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
by Zacks Equity Research
The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
The Zacks Analyst Blog Highlights NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm
by Zacks Equity Research
NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm are part of the Zacks top Analyst Blog.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Nasdaq Tops 17K: 5 Best-Performing Stocks in ETF YTD
by Sweta Killa
The Nasdaq Composite Index topped the 17,000 level for the first time. We have highlighted five best-performing stocks of QQQ this year that led the way higher in the portfolio.
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
by Zacks Equity Research
Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
by Zacks Equity Research
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
by Zacks Equity Research
Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
by Zacks Equity Research
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
by Zacks Equity Research
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
by Ekta Bagri
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
by Zacks Equity Research
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
Stock Market News for May 14, 2024
by Zacks Equity Research
Wall Street ended mixed on Monday as market participants sought insights into the Federal Reserve's rate cut plans.
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
by Zacks Equity Research
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
by Zacks Equity Research
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
Company News For May 13, 2024
by Zacks Equity Research
Companies In The Article Are:NVAX, SNY, MRNA, G and IAG.
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 14.48% and 33.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Moderna (MRNA)
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session.